ATP citrate lyase mediates resistance of colorectal cancer cells to SN38

Molecular Cancer Therapeutics

Volumn 12, Issue 12, 2013, Pages 2782-2791

  Zhou, Yunfei ^a   Bollu, Lakshmi Reddy ^c   Tozzi, Federico ^a   Ye, Xiangcang ^a   Bhattacharya, Rajat ^a   Gao, Guang ^c   Dupre, Elizabeth ^a   Xia, Ling ^a   Lu, Jia ^a   Fan, Fan ^a   Bellister, Seth ^a   Ellis, Lee M ^a,b   Weihua, Zhang ^c  

^a Departments of Systems Biology   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c University of Houston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE CITRATE LYASE; FIRTECAN; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PROTEIN KINASE B; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL; COLORECTAL CANCER; ENZYME INHIBITION; HUMAN; HUMAN CELL; LENTIVIRINAE; LIPOGENESIS; PRIORITY JOURNAL; UPREGULATION; VIRAL GENE DELIVERY SYSTEM;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ATP CITRATE (PRO-S)-LYASE; CAMPTOTHECIN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HT29 CELLS; HUMANS; MODELS, BIOLOGICAL; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE;

EID: 84890511382     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0098     Document Type: Article

References (46)

1. Davies JM, Goldberg RM. First-line therapeutic strategies in metastatic colorectal cancer. Oncology (Williston Park) 2008;22: 1470-9.
2. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360:563-72
3. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000;355:1041-7.
4. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.NEngl JMed 2000;343:905-14.
5. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991;51:4187-91.
6. Chen ZS, Furukawa T, Sumizawa T, Ono K, Ueda K, Seto K, et al. ATPdependent efflux f CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol 1999; 55:921-8.
7. Schellens JH, Maliepaard M, Scheper RJ, Scheffer GL, Jonker JW, Smit JW, et al. Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. Ann NY Acad Sci 2000;922:188-94.
8. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, et al. DNA opoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 1989;246:1046-8.
9. Kanzawa F, Sugimoto Y, Minato K, Kasahara K, Bungo M, NakagawaK, et al. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: Characterization and mechanism of resistance. Cancer Res 1990;50:5919-24.
10. Saleem A, Edwards TK, Rasheed Z, Rubin EH. Mechanisms of resistance to camptothecins. Ann N Y Acad Sci 2000;922:46-55.
11. Desai SD, Li TK, Rodriguez-Bauman A, Rubin EH, Liu LF. Ubiquitin/26S proteasome-mediated degradation of topoisomerase 1 as a resistance mechanism to camptothecin in tumor cells. Cancer Res 2001;61:5926-32.
12. Huang TT, Wuerzberger-Davis SM, Seufzer BJ, Shumway SD, Kurama T, Boothman DA, et al. NF-kappaB activation by camptothecin. A linkage between nuclear DNA damage and cytoplasmic signaling events. J Biol Chem 2000;275:9501-9.
13. Djiogue S, Nwabo Kamdje AH, Vecchio L, Kipanyula MJ, Farahna M, Aldebasi YH, et al. Insulin resistance and cancer: the role of insulin and insulin-like growth factors. Endocr Relat Cancer 2012;20:R1-17.
14. Hiller K, Metallo CM. Profiling metabolic networks to study cancer metabolism. Curr Opin Biotechnol 2013;24:60-8.
15. Tamada M, Nagano O, Tateyama S, Ohmura M, Yae T, Ishimoto T, et al. Modulation of glucose metabolismby CD44 contributes to antioxidant status and drug resistance in cancer cells. Cancer Res 2012;72: 1438-48.
16. Mashima T, Seimiya H, Tsuruo T. De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br J Cancer 2009;100:1369-72.
17. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011;11:85-95.
18. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
19. Zhang Y, Yang JM. Altered energy metabolism in cancer: A unique opportunity for therapeutic intervention. Cancer Biol Ther 2013; 14:81-9.
20. Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, van Buren G II, et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-1 receptor inhibition. Cancer Res 2009;69:1951-7.
21. Yang AD, Fan F,CampER, van Buren G, Liu W, Somcio R, et al. Chronic oxaliplatin esistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 2006;12:4147-53.
22. Bose D, Zimmerman LJ, Pierobon M, Petricoin E, Tozzi F, Parikh A, et al. Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells. Br J Cancer 2011; 105:1759-67.
23. Zu XY, Zhang QH, Liu JH, Cao RX, Zhong J, Yi GH, et al. ATP citrate lyase inhibitors as novel cancer therapeutic agents. Recent Pat Anticancer Drug Discov 2012;7:154-67.
24. Pearce NJ, Yates JW, Berkhout TA, Jackson B, Tew D, Boyd H, et al. The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB- 204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076. Biochem J 1998; 334:113-9.
25. Li JJ, Wang H, Tino JA, Robl JA, Herpin TF, Lawrence RM, et al. 2-hydroxy-N- arylbenzenesulfonamides as ATP-citrate lyase inhibitors.Bioorg Med Chem Lett 2007;17:3208-11.
26. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010;9:1956-67.
27. Gatti L, Zunino F. Overview of tumor cell chemoresistance mechanisms. Methods Mol Med 2005;111:127-48.
28. Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 2002; 13:1841-51.
29. Zhou Y, Tozzi F, Chen J, Fan F, Xia L, Wang J, et al. Intracellular ATP levels are a pivotal determinant of chemoresistance in colon cancer cells. Cancer Res 2012;72:304-14.
30. Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR, Thompson CB. ATP-citrate lyase links cellular metabolism to histone acetylation. Science 2009;324:1076-80.
31. Beckner ME, Fellows-Mayle W, Zhang Z, Agostino NR, Kant JA, Day BW, et al. Identification of ATP citrate lyase as a positive regulator of glycolytic function in glioblastomas. Int J Cancer 2010;126:2282-95.
32. Migita T, Narita T, Nomura K, Miyagi E, Inazuka F, Matsuura M, et al. ATP citrate lyase: Activation and therapeutic implications in non-small cell lung cancer. Cancer Res 2008;68:8547-54.
33. Szutowicz A, Kwiatkowski J, Angielski S. Lipogenetic and glycolytic enzyme activities in carcinoma and nonmalignant diseases of the human breast. Br J Cancer 1979;39:681-7.
34. Turyn J, Schlichtholz B, Dettlaff-Pokora A, Presler M, Goyke E, Matuszewski M, et al. Increased activity of glycerol 3-phosphate dehydrogenase and other lipogenic nzymes in human bladder cancer. Horm Metab Res 2003;35:565-9.
35. Varis A, Wolf M, Monni O, Vakkari ML, Kokkola A, Moskaluk C, et al. Targets of gene amplification and overexpression at 17q in gastric cancer. Cancer Res 2002;62:2625-9.
36. Wang Y, Wang Y, Shen L, Pang Y, Qiao Z, Liu P. Prognostic and therapeutic implications of increased ATP citrate lyase expression in human epithelial ovarian cancer. Oncol Rep 2012;27: 1156-62.
37. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007;7:763-77.
38. Potapova IA, El-Maghrabi MR, Doronin SV, Benjamin WB. Phosphorylation of recombinant human ATP: Citrate lyase by cAMP-dependent protein kinase abolishes homotropic allosteric regulation of the enzyme by citrate and increases the enzyme activity. Allosteric activation of ATP:citrate lyase by phosphorylated sugars. Biochemistry 2000;39:1169-79.
39. Zambell KL, Fitch MD, Fleming SE. Acetate and butyrate are the major substrates for de novo lipogenesis in rat colonic epithelial cells. J Nutr 2003;133:3509-15.
40. Yoshii Y, Waki A, Furukawa T, Kiyono Y, Mori T, Yoshii H, et al. Tumor uptake of radiolabeled acetate reflects the expression of cytosolic acetyl-CoA synthetase: implications for the mechanism of acetate PET. Nucl Med Biol 2009;36:771-7.
41. Wagner PD, Vu ND. Phosphorylation of ATP-citrate lyase by nucleoside diphosphate kinase. J Biol Chem 1995;270:21758-64.
42. Berwick DC, Hers I, Heesom KJ, Moule SK, Tavare JM. The identification of ATP-citrate lyase as a protein kinase B (Akt) substrate in primary adipocytes. J Biol Chem 2002;277:33895-900.
43. Bauer DE, Hatzivassiliou G, Zhao F, Andreadis C, Thompson CB. ATP citrate lyase is an important component of cell growth and transformation. Oncogene 2005;24:6314-22.
44. Porstmann T, Santos CR, Griffiths B, Cully M, Wu M, Leevers S, et al. SREBP activity is regulated by mTORC1 and contributes to Aktdependent cell growth. Cell Metab 2008;8:224-36.
45. Hanai J, Doro N, Sasaki AT, Kobayashi S, Cantley LC, Seth P, et al. Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3- kinase (PI3K)/AKT pathways. J Cell Physiol 2012;227:1709-20.
46. RobeyRB,HayN. Is Akt the "Warburg kinase"?-Akt-energymetabolism interactions and oncogenesis. Semin Cancer Biol 2009;19:25-31.